Page 68 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

92. Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific
marker for diagnosing bacterial infections in systemic lupus erythematosus
compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012;39(4):728-734.
93. Jung JY, Choi ST, Park SH, et al. Prevalence of osteoporosis in patients with
systemic lupus erythematosus: A multicenter comparative study of the World
Health Organization and fracture risk assessment tool criteria. Osteoporos
Sarcopenia. 2020;6(4):173-178.
94. Ballocca F, D’Ascenzo F, Moretti C, et al. Predictors of cardiovascular events
in patients with systemic lupus erythematosus (SLE): a systematic review and
meta-analysis. Eur J Prev Cardiol. 2015;22(11):1435-1441.
95. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic
lupus: an updated international multi-centre cohort study. J Autoimmun.
2013;42:130-135.
96. Clarke AE, Pooley N, Marjenberg Z, et al. Risk of malignancy in patients with
systemic lupus erythematosus: Systematic review and meta-analysis. Semin
Arthritis Rheum. 2021;51(6):1230-1241.
97. Yeo J, Seo MS, Hwang IC, et al. An Updated Meta-analysis on the Risk of
Urologic Cancer in Patients with Systemic Lupus Erythematosus. Arch Iran Med.
2020;23(9):614-620.
98. Schmajuk G, Yazdany J. Drug monitoring in systemic lupus erythematosus: a
systematic review. Semin Arthritis Rheum. 2011;40(6):559-575.
99. Gladman DD, Ibanez D, Ruiz I, et al. Recommendations for frequency of visits to
monitor systemic lupus erythematosus in asymptomatic patients: data from an
observational cohort study. J Rheumatol. 2013;40(5):630-633.
100. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for
the management of antiphospholipid syndrome in adults. Ann Rheum Dis.
2019;78(10):1296-1304.
101. Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies
in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84.
102. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and
immunologic manifestations and patterns of disease expression in a cohort of
1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027.
103. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international
cohorts further confirms the efficacy of aspirin for the primary prevention of
thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev.
2015;14(3):192-200.
104. Ministry of Health Malaysia. Perinatal Care Manual. 4th ed. Putrajaya: MOH;
2021.
105. He WR, Wei H. Maternal and fetal complications associated with systemic lupus
erythematosus: An updated meta-analysis of the most recent studies (2017-
2019). Medicine (Baltimore). 2020;99(16):e19797.
106. McDonald EG, Bissonette L, Ensworth S, et al. Monitoring of Systemic Lupus
Erythematosus Pregnancies: A Systematic Literature Review. J Rheumatol.
2018;45(10):1477-1490.
107. Shaharir SS, Maulana SA, Shahril NS, et al. Adverse pregnancy outcomes
among multi-ethnic systemic lupus erythematosus patients in Malaysia. Lupus.
2020;29(10):1305-1313.
108. Ferguson S, Trupin L, Yazdany J, et al. Who receives contraception counseling
when starting new lupus medications? The potential roles of race, ethnicity,
disease activity, and quality of communication. Lupus. 2016;25(1):12-17.
109. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive
methods in women with systemic lupus erythematosus. N Engl J Med.
2005;353(24):2539-2549.

51